{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:39:52Z","timestamp":1792373992151,"version":"4.4.0"},"reference-count":0,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite many advances in immunotherapies. Outcomes are particularly dismal in patients who are refractory to these three major classes of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies (mAbs), and chimeric antigen receptor (CAR) T-cell therapies. Novel bispecific antibodies (BsAbs) have shown some promising efficacy in heavily pretreated patients, even those with triple\u2010 and penta\u2010refractory disease. Talquetamab is a BsAb recently approved for the treatment of relapsed and refractory multiple myeloma. Talquetamab demonstrated a high overall response rate of approximately 70%, including in patients that are previously treated with T\u2010cell therapies. The safety profile of talquetamab is consistent with other BsAbs, with similar adverse events. The efficacy of talquetamab and other therapies, including CAR\u2010T cell treatments, remains an area of active research, as resistance to anti\u2010B-cell maturation antigen therapies poses a clinical challenge. Current trials are exploring the use of talquetamab in combination therapies. There is now adequate data to further support talquetamab\u2019s efficacy, making it a very important addition to the RRMM treatment domain.<\/jats:p>","DOI":"10.4103\/aam.aam_391_25","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:00:11Z","timestamp":1792371611000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Talquetamab and Its Effect on Relapsed and Refractory Multiple Myeloma"],"prefix":"10.4103","author":[{"given":"Naga Alekhya","family":"Garikipati","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, MediCiti Institute of Medical Sciences, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Vaishnavi","family":"Guntupalli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Guntur Medical College, Guntur, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh Kumar","family":"Korrapati","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NRI Medical College, Guntur, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahnavi","family":"Mikkilineni","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, ESIC Medical College and Hospital, Hyderabad, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinidhi","family":"Kondepudi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, NRI Medical College and Hospital, Guntur, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bushra","family":"Shaik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Piedmont Macon Hospital, Macon, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simhachalam","family":"Gurugubelli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, IUSOM, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rithish","family":"Nimmagadda","sequence":"additional","affiliation":[{"name":"One Brooklyn Health - Interfaith Medical Center, Brooklyn, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,19]]},"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_391_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:00:11Z","timestamp":1792371611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_391_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":0,"URL":"https:\/\/doi.org\/10.4103\/aam.aam_391_25","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"2025-08-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-05","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}